Literature DB >> 26152595

Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.

Hanne E H Møller1, Birgitte S Preiss1, Per Pedersen2, Ida B Kristensen3, Charlotte T Hansen3, Mikael Frederiksen4, Niels Abildgaard3, Michael B Møller1.   

Abstract

Multiple myeloma (MM) is a common malignant hematological disease displaying considerable heterogeneity. Historical data indicate a prognostic significance of plasmablastic morphology, proliferation, and adverse cytogenetics, but there is little knowledge on the degree of interdependency of these parameters. The aim of this study was to study the degree of overlap between these variables. In a consecutive population-based cohort of 194 untreated MM patients, morphology, and proliferation index, using immunohistochemical double staining for Ki-67 and CD138, was analyzed. In addition, cytogenetic changes were studied by karyotyping and fluorescence in situ hybridization (FISH). Plasmablastic morphology correlated with unfavorable clinical features, high proliferation index, high percentage of plasma cell infiltration in the bone marrow, abnormal karyotype, and del(13q) detected by karyotyping, which indicates that plasmablastic morphology reflects advanced and highly proliferative disease. However, plasmablastic morphology did not correlate with established adverse prognostic cytogenetics identified by FISH, for example, t(4;14), t(14;16) and del(17p).
© 2015 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Multiple myeloma; antigen Ki-67; cytogenetic abnormalities; fluorescent in situ hybridization; plasmablastic myeloma

Mesh:

Substances:

Year:  2015        PMID: 26152595     DOI: 10.1111/apm.12411

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  5 in total

1.  The colorful landscape of multiple myeloma.

Authors:  Eli Muchtar; Morie A Gertz
Journal:  Leuk Lymphoma       Date:  2019-02-27

2.  Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.

Authors:  Bo-Jung Chen; Chang-Tsu Yuan; Ching-Fen Yang; Chung-Han Ho; Yen-Kuang Lin; Ying-Zhen Su; Hsiu-Chu Chou; Shih-Sung Chuang
Journal:  Virchows Arch       Date:  2022-06-03       Impact factor: 4.535

3.  MYEOV gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32).

Authors:  Nicoletta Coccaro; Giuseppina Tota; Luisa Anelli; Antonella Zagaria; Paola Casieri; Angelo Cellamare; Crescenzio Francesco Minervini; Angela Minervini; Cosimo Cumbo; Luciana Impera; Claudia Brunetti; Paola Orsini; Elisa Parciante; Anna Mestice; Giorgina Specchia; Francesco Albano
Journal:  Oncol Lett       Date:  2016-06-22       Impact factor: 2.967

4.  HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report-Part 3.

Authors:  Amy Chadburn; Jonathan Said; Dita Gratzinger; John K C Chan; Daphne de Jong; Elaine S Jaffe; Yasodha Natkunam; John R Goodlad
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

5.  [The significance of bone marrow immature plasma cell burden in the prognosis of newly diagnosed multiple myeloma patients].

Authors:  Y L Li; J Shi; F Z Liu; X Y Dong; C Y Wu; W Cheng; Z F Huang; Z M Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-01-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.